Ross Kedl
13Patents
7h-index
12Co-inventors
59Inventor score
Filing activity: Aug 14, 2003 → Sep 10, 2015
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7387271B2 | Immunostimulatory combinations | Emerging Cross-Sectional Technologies | 137 | Expired |
| US7427629B2 | Immunostimulatory compositions and methods of stimulating an immune response | Emerging Cross-Sectional Technologies | 115 | Expired |
| US7993659B2 | TLR9 agonist and CD40 agonist immunostimulatory combinations | Emerging Cross-Sectional Technologies | 58 | Active |
| US8329197B2 | Ex vivo uses of immunostimulatory combinations | Emerging Cross-Sectional Technologies | 14 | Active |
| US9161976B2 | Immunotherapy comprising TLR9 ligand and CD40 ligand | Emerging Cross-Sectional Technologies | 12 | Active |
| US7993648B2 | Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody | Emerging Cross-Sectional Technologies | 12 | Active |
| US10105426B2 | Immunostimulatory combinations | Emerging Cross-Sectional Technologies | 8 | Active |
| US9801947B2 | Methods and compositions for enhancing immune response | Emerging Cross-Sectional Technologies | 7 | Active |
| US8361471B2 | Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody | Emerging Cross-Sectional Technologies | 3 | Active |
| US8137672B2 | Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody | Emerging Cross-Sectional Technologies | 3 | Active |
| US8961477B2 | Delivery of immune response modifier compounds | Human Necessities | 1 | Active |
| US10329338B2 | Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon | Emerging Cross-Sectional Technologies | 0 | Active |
| US9095608B2 | Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.